Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Abbott To Purchase Russia’s Veropharm
by Ann M. Thayer
June 30, 2014
| A version of this story appeared in
Volume 92, Issue 26
Abbott Laboratories has agreed to acquire Veropharm, a Russian pharmaceutical manufacturer. It will pay between $395 million and $495 million to purchase the holding company that now owns more than 80% of Veropharm and is expected to own 95% by the time the deal is completed. Abbott will also assume about $135 million in debt. The business will add about 100 products and $150 million in annual sales in 2015. The acquisition will provide a new manufacturing base for Abbott, which has operated in Russia for 36 years.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter